Beacon Biosignals, Inc. — SEC Form D Filing
Beacon Biosignals, Inc. filed an SEC Form D on April 15, 2026, reporting $103.28M raised in Healthcare Technology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- April 15, 2026
- Amount reported
- $103.28M
- Round stage
- Series B+
- Industry
- Healthcare Technology
- Website
- https://beacon.bio/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Many patients suffer from neurological and psychiatric conditions without effective treatments due to the complexity of the brain. This gap leads to a lack of answers and adequate care.
Solution
Beacon Biosignals uses AI-driven neurotechnology to provide precise neuroscience insights for clinical trials, enabling faster and more effective drug development for unmet medical needs.
Verdict
Investors said yes because they recognized a pressing need for innovation in treating neurological and psychiatric disorders, not because existing solutions were meeting that demand. They were implicitly betting on the transformative potential of AI in neuroscience, particularly in clinical trial applications. However, the limited upside stems from the over-saturation of AI applications in healthcare, which raises questions about Beacon Biosignals' unique value proposition and long-term market viability.
Source: SEC EDGAR Form D filing